Aisha Khan, MSc, MBA

Aisha Khan, MSc, MBA

Aisha has twenty years of professional experience in medical, manufacturing, quality assurance, regulatory, and service related environments. While working at the University of Miami’s GMP facility, she has setup and managed many national and international state of the art research facilities. She routinely provides guidance to GMP facilities that are at various levels of maturity in their lifecycle to become FDA compliant. She has several years of experience and knowledge of FDA regulations, and practices regarding GMP in research facilities. She has served as the manufacturing and regulatory representative in Global Islet manufacturing team and provided US/EU regulatory input to various international organizations.

Aisha’s research interests include stem cell therapy, islet cell transplantation, spinal cord injury and regulatory issues and quality assurance. She is specialized in cell biology, microbiology, immunology, neuroscience and biochemistry. Her main focus is on optimization of stem cell culture techniques, specifically in these areas: 1) perfecting the culture methods and technique 2) in vitro assessment of stem cell potency and characterization 3) factors involved in stem cell growth and differentiation 4) also, optimizing islet isolation and transplantation techniques 5) developing cell characterization for Schwann cells and extensive experience in development of c-kit+ Cardiac Progenitor Stem Cells.

Proven leader to successfully analyze an organization’s critical business requirements, identify deficiencies and potential opportunities, and develop innovative and cost-effective solutions for enhancing competitiveness, increasing revenues, and improving quality of service.

She is an active member of American Association of Blood Bank (AABB), International Society of Cellular Therapy (ISCT), Regulatory Affairs Professional Society (RAPS), American Heart Association and Cells Transplant Society. She has the unique honor of performing the first successful Asian Pancreatic Islet Cell Transplant at Shanghai First People’s Hospital in China on January 26, 2003.